{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:10:03Z","timestamp":1751422203803,"version":"3.41.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U2004119"],"award-info":[{"award-number":["U2004119"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-00062-x","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:38:31Z","timestamp":1751420311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase II study of transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced perihilar cholangiocarcinoma"],"prefix":"10.1038","volume":"15","clinical-trial-number":[{"clinical-trial-number":"chictr2000035178","registry":"10.18810\/chictr"}],"author":[{"given":"Hao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengfan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanbang","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baohong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhuang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuhua","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"9","key":"62_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nrgastro.2011.131","volume":"8","author":"B BLECHACZ","year":"2011","unstructured":"BLECHACZ, B. et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat. Reviews Gastroenterol. Hepatol. 8(9), 512\u2013522 (2011).","journal-title":"Nat. Reviews Gastroenterol. Hepatol."},{"issue":"5","key":"62_CR2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","volume":"245","author":"DEOLIVEIRA M L","year":"2007","unstructured":"DEOLIVEIRA M L et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann. Surg. 245(5), 755\u2013762 (2007).","journal-title":"Ann. Surg."},{"issue":"8","key":"62_CR3","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","volume":"15","author":"D MALKA","year":"2014","unstructured":"MALKA, D. & CERVERA, P. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): A randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 15(8), 819\u2013828 (2014).","journal-title":"Lancet Oncol."},{"issue":"14","key":"62_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J VALLE","year":"2010","unstructured":"VALLE, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362(14), 1273\u20131281 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"62_CR5","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/jamaoncol.2018.3277","volume":"4","author":"SAHAIV CATALANO P J","year":"2018","unstructured":"CATALANO P J, S. A. H. A. I. V. et al. Nab-Paclitaxel and gemcitabine as First-line treatment of advanced or metastatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol. 4(12), 1707\u20131712 (2018).","journal-title":"JAMA Oncol."},{"issue":"2","key":"62_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/annonc\/mdt540","volume":"25","author":"JW VALLE","year":"2014","unstructured":"VALLE, J. W. et al. Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomised trials. Ann. Oncol. 25(2), 391\u2013398 (2014).","journal-title":"Ann. Oncol."},{"issue":"8","key":"62_CR7","doi-asserted-by":"publisher","first-page":"e0134857","DOI":"10.1371\/journal.pone.0134857","volume":"10","author":"DUAN X-H","year":"2015","unstructured":"DUAN X-H et al. Intraductal radiofrequency ablation followed by locoregional tumor treatments for treating occluded biliary stents in Non-Resectable malignant biliary obstruction: A Single-Institution experience. PLoS One 10(8), e0134857 (2015).","journal-title":"PLoS One"},{"issue":"1","key":"62_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0284185116632386","volume":"58","author":"Z LI","year":"2017","unstructured":"LI, Z. et al. Value of percutaneous transhepatic cholangiobiopsy for pathologic diagnosis of obstructive jaundice: Analysis of 826 cases. Acta Radiol. 58(1), 3\u20139 (2017).","journal-title":"Acta Radiol."},{"issue":"11","key":"62_CR9","doi-asserted-by":"publisher","first-page":"e19545","DOI":"10.1097\/MD.0000000000019545","volume":"99","author":"LIUB CHANG H-Y","year":"2020","unstructured":"CHANG H-Y, L. I. U. B. et al. Percutaneous transhepatic cholangiography versus endoscopic retrograde cholangiography for the pathological diagnosis of suspected malignant bile duct strictures. Med. (Baltim). 99(11), e19545 (2020).","journal-title":"Med. (Baltim)."},{"issue":"3","key":"62_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000367739","volume":"4","author":"M TSURUSAKI","year":"2015","unstructured":"TSURUSAKI, M. Surgical and locoregional therapy of HCC: TACE. Liver Cancer. 4(3), 165\u2013175 (2015).","journal-title":"Liver Cancer"},{"issue":"2","key":"62_CR11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1148\/radiol.2016160572","volume":"283","author":"X WANG","year":"2017","unstructured":"WANG, X. et al. Phase II study of hepatic arterial infusion chemotherapy with oxaliplatin and 5-Fluorouracil for advanced Perihilar cholangiocarcinoma. Radiology 283(2), 580\u2013589 (2017).","journal-title":"Radiology"},{"issue":"4","key":"62_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.14740\/jocmr2496w","volume":"8","author":"K LIU","year":"2016","unstructured":"LIU, K. et al. The changes of HIF-1\u03b1 and VEGF expression after TACE in patients with hepatocellular carcinoma. J. Clin. Med. Res. 8(4), 297\u2013302 (2016).","journal-title":"J. Clin. Med. Res."},{"issue":"5","key":"62_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM LLOVET","year":"2021","unstructured":"LLOVET, J. M. et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat. Reviews Gastroenterol. Hepatol. 18(5), 293\u2013313 (2021).","journal-title":"Nat. Reviews Gastroenterol. Hepatol."},{"key":"62_CR14","doi-asserted-by":"crossref","unstructured":"VIVEIROS, P. & RIAZ, A. LEWANDOWSKI R J, et al. Current state of Liver-Directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC). Cancers 11(8) (2019).","DOI":"10.3390\/cancers11081085"},{"issue":"1","key":"62_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12876-018-0870-3","volume":"18","author":"M HUANG","year":"2018","unstructured":"HUANG, M. et al. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2\/RAF\/MEK\/ERK and PI3K\/AKT pathways in cholangiocarcinoma cell. BMC Gastroenterol. 18(1), 169 (2018).","journal-title":"BMC Gastroenterol."},{"issue":"13","key":"62_CR16","doi-asserted-by":"publisher","first-page":"17220","DOI":"10.18632\/oncotarget.7948","volume":"7","author":"H PENG","year":"2016","unstructured":"PENG, H. et al. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget 7(13), 17220\u201317229 (2016).","journal-title":"Oncotarget"},{"key":"62_CR17","doi-asserted-by":"crossref","unstructured":"HUANG M-P, GU S-Z, H. U. A. N. G. B. et al. Apatinib inhibits angiogenesis in intrahepatic cholangiocarcinoma by regulating the vascular endothelial growth factor receptor-2\/signal transducer and activator of transcription factor 3\/hypoxia inducible factor 1 subunit alpha signaling Axis. Pharmacol. 106(9\u201310), 509\u2009\u2013\u200919. (2021).","DOI":"10.1159\/000514410"},{"key":"62_CR18","doi-asserted-by":"crossref","unstructured":"ZHANG, G. et al. PANG L,. Efficacy and safety of apatinib treatment for advanced cholangiocarcinoma after failed gemcitabine-based chemotherapy: An open-label phase II prospective study. Front Oncol. 11, 659217 (2021).","DOI":"10.3389\/fonc.2021.659217"},{"issue":"1","key":"62_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12885-021-07907-4","volume":"21","author":"C NIE","year":"2021","unstructured":"NIE, C. et al. The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: A retrospective study. BMC Cancer 21(1), 189 (2021).","journal-title":"BMC Cancer"},{"issue":"5","key":"62_CR20","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.7150\/jca.53482","volume":"12","author":"J MAO","year":"2021","unstructured":"MAO, J. et al. Apatinib as non-first-line treatment in patients with intrahepatic cholangiocarcinoma. J. Cancer 12(5), 1555\u20131562 (2021).","journal-title":"J. Cancer"},{"key":"62_CR21","doi-asserted-by":"crossref","unstructured":"SIMON R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials 10(1) (1989).","DOI":"10.1016\/0197-2456(89)90015-9"},{"issue":"12","key":"62_CR22","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C MORIZANE","year":"2019","unstructured":"MORIZANE, C. et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann. Oncol. 30(12), 1950\u20131958 (2019).","journal-title":"Ann. Oncol."},{"issue":"10391","key":"62_CR23","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"UENOM KELLEY RK","year":"2023","unstructured":"KELLEY RK, U. E. N. O. M. et al. KEYNOTE-966 investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401 (10391), 1853\u20131865 (2023).","journal-title":"Lancet"},{"issue":"12","key":"62_CR24","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1136\/gut.33.12.1675","volume":"33","author":"T KURZAWINSKI","year":"1992","unstructured":"KURZAWINSKI, T. et al. A prospective controlled study comparing brush and bile exfoliative cytology for diagnosing bile duct strictures. Gut 33(12), 1675\u20131677 (1992).","journal-title":"Gut"},{"issue":"5","key":"62_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5306\/wjco.v2.i5.203","volume":"2","author":"K TAMADA","year":"2011","unstructured":"TAMADA, K. & USHIO, J. Endoscopic diagnosis of extrahepatic bile duct carcinoma: Advances and current limitations. World J. Clin. Oncol. 2(5), 203\u2013216 (2011).","journal-title":"World J. Clin. Oncol."},{"issue":"4","key":"62_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1590\/0100-3984.2018.0073","volume":"52","author":"TIBANA T K","year":"2019","unstructured":"TIBANA T K et al. The role of percutaneous transhepatic biliary biopsy in the diagnosis of patients with obstructive jaundice: An initial experience. Radiol. Bras. 52(4), 222\u2013228 (2019).","journal-title":"Radiol. Bras."},{"issue":"1","key":"62_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2342-4-3","volume":"4","author":"M ROSSI","year":"2004","unstructured":"ROSSI, M. et al. Histologic assessment of biliary obstruction with different percutaneous endoluminal techniques. BMC Med. Imaging 4(1), 3 (2004).","journal-title":"BMC Med. Imaging"},{"issue":"43","key":"62_CR28","doi-asserted-by":"publisher","first-page":"e8372","DOI":"10.1097\/MD.0000000000008372","volume":"96","author":"Z TANG","year":"2017","unstructured":"TANG, Z. et al. Best option for preoperative biliary drainage in Klatskin tumor: A systematic review and meta-analysis. Med. (Baltim). 96(43), e8372 (2017).","journal-title":"Med. (Baltim)."},{"issue":"10","key":"62_CR29","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s11095-012-0775-8","volume":"29","author":"DE AIT-OUDHIA S, STRAUBINGER R M, MAGE","year":"2012","unstructured":"AIT-OUDHIA S, STRAUBINGER R M, MAGER, D. E. Meta-analysis of nanoparticulate Paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm. Res. 29(10), 2833\u20132844 (2012).","journal-title":"Pharm. Res."},{"issue":"1","key":"62_CR30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.1995.13.1.180","volume":"13","author":"GIANNIL KEARNS C","year":"1995","unstructured":"KEARNS C, G. I. A. N. N. I. L. & GIANI, M. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic\/pharmacodynamic relationships in humans. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 13(1), 180\u2013190 (1995).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"issue":"31","key":"62_CR31","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"S GRADISHAR W J, TJULANDIN","year":"2005","unstructured":"GRADISHAR W J, TJULANDIN, S. et al. Phase III trial of nanoparticle albumin-bound Paclitaxel compared with polyethylated castor oil-based Paclitaxel in women with breast cancer. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 23(31), 7794\u20137803 (2005).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"62_CR32","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","volume":"69","author":"M KUDO","year":"2020","unstructured":"KUDO, M. et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus Sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 69, 1492\u20131501 (2020).","journal-title":"Gut"},{"key":"62_CR33","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1002\/cam4.1664","volume":"7","author":"C YANG","year":"2018","unstructured":"YANG, C. & QIN, S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. Cancer Med. 7, 4570\u20134583 (2018).","journal-title":"Cancer Med."},{"key":"62_CR34","doi-asserted-by":"publisher","first-page":"766","DOI":"10.4254\/wjh.v12.i10.766","volume":"12","author":"XH ZHANG","year":"2020","unstructured":"ZHANG, X. H. et al. Apatinib as an alternative therapy for advanced hepatocellular carcinoma. World J. Hepatol. 12, 766\u2013774 (2020).","journal-title":"World J. Hepatol."},{"key":"62_CR35","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.2147\/OTT.S172717","volume":"11","author":"JM XUE","year":"2018","unstructured":"XUE, J. M. et al. Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: A meta-analysis. Onco Targets Ther. 11, 6119\u20136128 (2018).","journal-title":"Onco Targets Ther."},{"issue":"3","key":"62_CR36","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1148\/radiol.13130009","volume":"270","author":"MJ PARK","year":"2014","unstructured":"PARK, M. J. et al. Hilar cholangiocarcinoma: value of adding DW imaging to Gadoxetic acid-enhanced MR imaging with MR cholangiopancreatography for preoperative evaluation. Radiology 270(3), 768\u2013776 (2014).","journal-title":"Radiology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00062-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:38:34Z","timestamp":1751420314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00062-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-00062-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This single-arm single-center phase II clinical trial was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"22867"}}